Oncoinvent ASA (OSL:ONCIN) Short Percentage of Float


OSL:ONCIN Oncoinvent ASA OSL:ONCIN
37 GF Score
Price kr66.00
GF Value kr972.79
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

OSL:ONCIN vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Oncoinvent ASA's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncoinvent ASA Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Oncoinvent ASA's Short Percentage of Float falls into.


OSL:ONCIN
37GF Score
Oncoinvent ASA OSL:ONCIN
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncoinvent ASA (OSL:ONCIN) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr66.00 is trading 93.2% below its estimated GF Value™ of kr972.79. GuruFocus considers Oncoinvent ASA to be Possible Value Trap.

Key valuation signals for OSL:ONCIN:

  • Short Percentage of Float:
  • GF Value™: kr972.79 vs. price of kr66.00 (93.2% below fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the OSL:ONCIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Other Exchanges 0RU5:UK7BG:Germany
Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
37GF Score

Get the complete analysis for OSL:ONCIN

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr66.00
Price
kr972.79
GF Value